$0.8479
-0.30-26.27%
Last update: Jun 8, 11:00 AM
Standard BioTools Inc Analyst Ratings
LABNASDAQ
PRO
M&A: Treeline Biosciences, Inc announced today it will be merged with Standard BioTools (LAB) for $450.0M paid in stock
Standard BioTools Analyst Ratings and Price Targets | NASDAQ:LAB | Benzinga
Standard BioTools Inc has a consensus price target of $2.37 based on the ratings of 4 analysts. The high is $3.25 issued by Jefferies on April 4, 2024. The low is $1.35 issued by TD Cowen on November 5, 2025. The 3 most-recent analyst ratings were released by TD Cowen on November 5, 2025, October 31, 2024, and August 1, 2024, respectively. With an average price target of $2.2 between TD Cowen, there's an implied 159.46% upside for Standard BioTools Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
TD Cowen
TD Cowen
Jefferies
1calculated from analyst ratings
Analyst Ratings for Standard BioTools
Loading calendar...
FAQ
What is the target price for Standard BioTools (LAB) stock?
The latest price target for Standard BioTools (NASDAQ:LAB) was reported by TD Cowen on November 5, 2025. The analyst firm set a price target for $1.35 expecting LAB to rise to within 12 months (a possible 59.22% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Standard BioTools (LAB)?
The latest analyst rating for Standard BioTools (NASDAQ:LAB) was provided by TD Cowen, and Standard BioTools maintained their hold rating.
When was the last upgrade for Standard BioTools (LAB)?
There is no last upgrade for Standard BioTools
When was the last downgrade for Standard BioTools (LAB)?
The last downgrade for Standard BioTools Inc happened on February 27, 2025 when Keybanc changed their price target from N/A to N/A for Standard BioTools Inc.
When is the next analyst rating going to be posted or updated for Standard BioTools (LAB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Standard BioTools, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Standard BioTools was filed on November 5, 2025 so you should expect the next rating to be made available sometime around November 5, 2026.
Is the Analyst Rating Standard BioTools (LAB) correct?
While ratings are subjective and will change, the latest Standard BioTools (LAB) rating was a maintained with a price target of $1.55 to $1.35. The current price Standard BioTools (LAB) is trading at is $0.85, which is out of the analyst’s predicted range.
